Home > Press > Los Alamos National Laboratory Announces Selection of Venture Acceleration Fund Recipients: Hundred-thousand-dollar awards to pair of firms
Abstract:
Los Alamos National Laboratory (LANL) has selected Manhattan Isotopes Technology, LLC and Vista Therapeutics, Inc. as recipients of $100,000 awards from the Los Alamos National Security, LLC Venture Acceleration Fund.
The Venture Acceleration Fund (VAF) invests in innovative Northern New Mexico companies seeking to commercialize technology and take it to market faster. VAF investments help the companies and their technologies reach the next level of success through business development activities such as proof-of-concept, prototyping, securing initial customers, or additional funding. Projects with an association with LANL technology or expertise receive preference for funding.
The VAF program fills a unique need by providing capital that reduces a company's risk. "Without this type of funding, projects can languish or take much longer to come to fruition," says said David Pesiri, the Laboratory's Technology Transfer Division leader. "Our team also works closely with the companies during their contract period to connect them with other resources—like mentors, customers, and contacts—that will make them more successful in the long run.
Manhattan Isotope Technology, LLC is a Los Alamos start-up company that will supply the active pharmaceutical ingredient strontium-82 to radiopharmaceutical companies for heart-imaging purposes. Until now, drug producers requiring strontium-82 have been mostly limited to Los Alamos National Laboratory and Brookhaven National Laboratory. Manhattan Isotope Technology will decrease the manufacturing burden on the U.S. government by commercializing LANL's patented strontium-82 production technology, which produces the ingredient by recycling expired strontium-82/rubidium-82 generators. Manhattan Isotope Technology's $100,000 VAF award will enable the company to develop, test, and validate a radioanalytical lab for strontium-82 manufacturing, establish environmental compliance, and gain acceptance from pharmaceutical manufacturers. The core project team includes Jason Kitten, Suzanne Kitten, and Larry Pitt.
Vista Therapeutics Inc. has developed NanoBioSensor™ technology that will revolutionize the measurement of biomarkers, such as proteins produced in response to trauma or disease. While existing biomarker measurement systems rely on occasional "snapshots" and expensive and time-consuming analysis, Vista's system will enable screening and immediate test results for large numbers of people, as well as continuous bedside monitoring. Vista will use its $100,000 VAF award to apply a novel technology for attaching antibodies to a silicon oxide surface in the company's Santa Fe facilities. This will enable the company to launch its first products in early 2012. The core project team includes Charles Lieber, Ph.D.; Spencer Farr, Ph.D.; Noah Clay, Ph.D.; and Mark Walztoni. Vista anticipates hiring 17 additional full-time, high wage employees by the end of 2013.
Los Alamos National Security, LLC, manager of Los Alamos National Laboratory, invests $1 million per year in economic development through a program known as Northern New Mexico Connect. Northern New Mexico Connect promotes VAF and a variety of other business
development programs. In the past seven years, companies have created and retained 168 jobs and attracted $7 million in new funding and financing as a result of their work with Northern New Mexico Connect.
####
About Los Alamos National Laboratory
Los Alamos National Laboratory, a multidisciplinary research institution engaged in strategic science on behalf of national security, is operated by Los Alamos National Security, LLC, a team composed of Bechtel National, the University of California, The Babcock & Wilcox Company, and URS for the Department of Energy’s National Nuclear Security Administration.
Los Alamos enhances national security by ensuring the safety and reliability of the U.S. nuclear stockpile, developing technologies to reduce threats from weapons of mass destruction, and solving problems related to energy, environment, infrastructure, health, and global security concerns.
For more information, please click here
Contacts:
Jeff Berger
505-665-9178
Copyright © Los Alamos National Laboratory
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Laboratories
A battery’s hopping ions remember where they’ve been: Seen in atomic detail, the seemingly smooth flow of ions through a battery’s electrolyte is surprisingly complicated February 16th, 2024
NRL discovers two-dimensional waveguides February 16th, 2024
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Govt.-Legislation/Regulation/Funding/Policy
New discovery aims to improve the design of microelectronic devices September 13th, 2024
Physicists unlock the secret of elusive quantum negative entanglement entropy using simple classical hardware August 16th, 2024
Single atoms show their true color July 5th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||